Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 3.01
(-1.63%)
CNY 3.01
(-1.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.03 Billion CNY | -34.74% |
| 2022 | 12.31 Billion CNY | -41.54% |
| 2021 | 21.05 Billion CNY | -22.59% |
| 2020 | 27.2 Billion CNY | -22.84% |
| 2019 | 35.25 Billion CNY | 3.95% |
| 2018 | 33.91 Billion CNY | 45.61% |
| 2017 | 23.29 Billion CNY | 49.14% |
| 2016 | 15.61 Billion CNY | 60.19% |
| 2015 | 9.74 Billion CNY | 25.23% |
| 2014 | 7.78 Billion CNY | 31.39% |
| 2013 | 5.92 Billion CNY | 28.2% |
| 2012 | 4.62 Billion CNY | 44.65% |
| 2011 | 3.19 Billion CNY | 44.37% |
| 2010 | 2.21 Billion CNY | 38.19% |
| 2009 | 1.6 Billion CNY | 39.63% |
| 2008 | 1.14 Billion CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 2.01 Billion CNY | 1.07% |
| 2024 Q1 | 2.01 Billion CNY | 4.64% |
| 2024 Q2 | 2 Billion CNY | -0.77% |
| 2023 Q3 | 2.02 Billion CNY | 0.91% |
| 2023 Q4 | 1.92 Billion CNY | -4.73% |
| 2023 FY | 8.03 Billion CNY | -34.74% |
| 2023 Q1 | 2.07 Billion CNY | 46.55% |
| 2023 Q2 | 2 Billion CNY | -3.19% |
| 2022 Q3 | 3.34 Billion CNY | -3.24% |
| 2022 Q4 | 1.41 Billion CNY | -57.72% |
| 2022 FY | 12.31 Billion CNY | -41.54% |
| 2022 Q1 | 4.09 Billion CNY | 19.55% |
| 2022 Q2 | 3.45 Billion CNY | -15.53% |
| 2021 FY | 21.05 Billion CNY | -22.59% |
| 2021 Q2 | 6.94 Billion CNY | 20.5% |
| 2021 Q3 | 4.92 Billion CNY | -29.1% |
| 2021 Q4 | 3.42 Billion CNY | -30.47% |
| 2021 Q1 | 5.76 Billion CNY | -19.93% |
| 2020 Q4 | 7.19 Billion CNY | -1.62% |
| 2020 Q3 | 7.31 Billion CNY | 5.7% |
| 2020 FY | 27.2 Billion CNY | -22.84% |
| 2020 Q1 | 5.76 Billion CNY | -30.68% |
| 2020 Q2 | 6.92 Billion CNY | 20.12% |
| 2019 Q2 | 9.21 Billion CNY | 5.42% |
| 2019 Q3 | 8.98 Billion CNY | -2.48% |
| 2019 FY | 35.25 Billion CNY | 3.95% |
| 2019 Q1 | 8.74 Billion CNY | -6.63% |
| 2019 Q4 | 8.31 Billion CNY | -7.49% |
| 2018 Q3 | 9.04 Billion CNY | 8.0% |
| 2018 FY | 33.91 Billion CNY | 45.61% |
| 2018 Q4 | 9.36 Billion CNY | 3.47% |
| 2018 Q2 | 8.37 Billion CNY | 17.52% |
| 2018 Q1 | 7.12 Billion CNY | 7.36% |
| 2017 FY | 23.29 Billion CNY | 49.14% |
| 2017 Q3 | 6.25 Billion CNY | 15.61% |
| 2017 Q4 | 6.64 Billion CNY | 6.08% |
| 2017 Q2 | 5.41 Billion CNY | 8.75% |
| 2017 Q1 | 4.97 Billion CNY | 5.3% |
| 2016 FY | 15.61 Billion CNY | 60.19% |
| 2016 Q2 | 3.67 Billion CNY | 13.34% |
| 2016 Q3 | 3.97 Billion CNY | 8.09% |
| 2016 Q4 | 4.72 Billion CNY | 19.02% |
| 2016 Q1 | 3.24 Billion CNY | 19.61% |
| 2015 Q2 | 2.3 Billion CNY | 4.96% |
| 2015 Q3 | 2.53 Billion CNY | 10.09% |
| 2015 Q4 | 2.71 Billion CNY | 6.83% |
| 2015 FY | 9.74 Billion CNY | 25.23% |
| 2015 Q1 | 2.19 Billion CNY | 0.57% |
| 2014 Q3 | 2.02 Billion CNY | 9.75% |
| 2014 Q2 | 1.84 Billion CNY | 5.7% |
| 2014 Q1 | 1.74 Billion CNY | 14.2% |
| 2014 FY | 7.78 Billion CNY | 31.39% |
| 2014 Q4 | 2.18 Billion CNY | 8.09% |
| 2013 Q2 | 1.46 Billion CNY | 9.08% |
| 2013 FY | 5.92 Billion CNY | 28.2% |
| 2013 Q4 | 1.52 Billion CNY | -3.95% |
| 2013 Q3 | 1.58 Billion CNY | 8.16% |
| 2013 Q1 | 1.34 Billion CNY | 8.59% |
| 2012 Q4 | 1.23 Billion CNY | -2.17% |
| 2012 Q3 | 1.26 Billion CNY | 13.24% |
| 2012 Q2 | 1.11 Billion CNY | 12.07% |
| 2012 Q1 | 998.03 Million CNY | 4.8% |
| 2012 FY | 4.62 Billion CNY | 44.65% |
| 2011 FY | 3.19 Billion CNY | 44.37% |
| 2011 Q3 | 865.47 Million CNY | 16.13% |
| 2011 Q2 | 745.25 Million CNY | 17.84% |
| 2011 Q1 | 632.44 Million CNY | 3.34% |
| 2011 Q4 | 952.28 Million CNY | 10.03% |
| 2010 Q2 | 565.59 Million CNY | 30.48% |
| 2010 Q4 | 611.99 Million CNY | 1.61% |
| 2010 FY | 2.21 Billion CNY | 38.19% |
| 2010 Q1 | 433.47 Million CNY | 0.0% |
| 2010 Q3 | 602.3 Million CNY | 6.49% |
| 2009 FY | 1.6 Billion CNY | 39.63% |
| 2008 FY | 1.14 Billion CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 75.47 Billion CNY | 89.355% |
| Shenzhen Glory Medical Co.,Ltd. | 1.19 Billion CNY | -573.523% |